Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 9

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 9
---
. Due to resource constraints, MTX110 has been de-prioritized.

| 5 |

Our clinical assets are supported by three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of drugs through either sustained delivery (Q-Sphera TM), direct delivery (MidaSolve TM), or targeted delivery (MidaCore TM):

| · | Our Q-Sphera platform: Our disruptive polymer microsphere microtechnology                                                                
 is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. |

| · | Our MidaSolve platform: Our innovative oligosaccharide nanotechnology                                         
 is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors. |

| · | MidaCore platform: Our gold nanoparticle nanotechnology is used                                     
 for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents. |

We are currently focused on our clinical stage assets eRapa and tolimidone and there are no active research and development programs based on our drug delivery technologies. Financial Update As of September 30, 2025, we had cash and cash equivalents of £2.79 million. Financial information as of September 30, 2025 in this prospectus has not been audited and has been prepared by, and is the responsibility of, our management. This data could change as a result of further review. In addition, our independent registered public accounting firm has not audited, reviewed, compiled, or performed any procedures with respect to this unaudited financial information and does not express an opinion or any other form of assurance with respect thereto. Accordingly, you should not place undue reliance on this information. Additional information and disclosures would be required for a more complete understanding of our financial condition, liquidity, and results of operations as of September 30, 2025. Complete annual results will be included in our Annual Report on Form 20-F for the year ended December 31, 2025. Recent Developments Ratio Change On July 31, 2025, we effected a ratio change in the number of Ordinary Shares represented by our Depositary Shares from 10,000 Ordinary Shares per Depositary Share to 100,000 Ordinary Shares per Depositary Share. No fractional Depositary Shares were issued. June 2025 GM On June 11, 2025, we held the June 2025 GM and our shareholders passed